Amicus Therapeutics (NASDAQ:FOLD) Receives Sell (E+) Rating from Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (E+)" rating for Amicus Therapeutics, indicating a negative outlook for the stock.
• Amicus Therapeutics' average target price is $15.88, with the stock currently trading around $8.69, reflecting a significant potential upside.
• A mix of analyst ratings includes one "Strong Buy", seven "Buy", one "Hold", and one "Sell", showing varied investor sentiment toward the company's future performance.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report)'s stock had its "sell (e+)" rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

A number of other equities research analysts have also recently weighed in on the company. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, October 18th. Needham & Company LLC raised Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 price target for the company in a report on Thursday, September 18th. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Finally, Zacks Research raised shares of Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.88.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD traded up $0.19 during mid-day trading on Friday, hitting $8.69. 2,036,227 shares of the stock were exchanged, compared to its average volume of 4,093,182. Amicus Therapeutics has a twelve month low of $5.51 and a twelve month high of $12.65. The stock's fifty day simple moving average is $8.00 and its two-hundred day simple moving average is $6.92. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The company has a market cap of $2.68 billion, a P/E ratio of -72.47 and a beta of 0.56.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. raised its position in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 3,677 shares during the last quarter. Strs Ohio bought a new stake in shares of Amicus Therapeutics during the 1st quarter valued at $30,000. PNC Financial Services Group Inc. raised its position in shares of Amicus Therapeutics by 211.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 3,497 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Amicus Therapeutics during the 1st quarter valued at $53,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.